Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xtant Medical Holdings (XTNT) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Xtant Medical Holdings (XTNT) over the last 17 years, with Q3 2025 value amounting to $11.7 million.

  • Xtant Medical Holdings' Cost of Revenue fell 121.11% to $11.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.7 million, marking a year-over-year decrease of 286.28%. This contributed to the annual value of $49.2 million for FY2024, which is 2803.14% up from last year.
  • As of Q3 2025, Xtant Medical Holdings' Cost of Revenue stood at $11.7 million, which was down 121.11% from $11.6 million recorded in Q2 2025.
  • Xtant Medical Holdings' Cost of Revenue's 5-year high stood at $13.2 million during Q2 2024, with a 5-year trough of $4.9 million in Q1 2021.
  • Over the past 5 years, Xtant Medical Holdings' median Cost of Revenue value was $8.7 million (recorded in 2023), while the average stood at $9.1 million.
  • In the last 5 years, Xtant Medical Holdings' Cost of Revenue plummeted by 2429.44% in 2021 and then surged by 6882.42% in 2023.
  • Quarter analysis of 5 years shows Xtant Medical Holdings' Cost of Revenue stood at $6.3 million in 2021, then increased by 10.98% to $7.0 million in 2022, then skyrocketed by 66.34% to $11.6 million in 2023, then rose by 0.86% to $11.7 million in 2024, then grew by 0.53% to $11.7 million in 2025.
  • Its last three reported values are $11.7 million in Q3 2025, $11.6 million for Q2 2025, and $12.7 million during Q1 2025.